Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

J, Baselga; V, Semiglazov; Dam P, van; A, Manikhas; M, Bellet; J, Mayordomo; M, Campone; E, Kubista; R, Greil; G, Bianchi; J, Steinseifer; B, Molloy; E, Tokaji; H, Gardner; P, Phillips; M, Stumm; HA, Lane; JM, Dixon; W, Jonat; HS, Rugo

doi:10.1200/jco.2008.18.8391

Public

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Shared by NobleBlocks on Apr 20, 2009 • 12:00 AM UTC

Authors:

Baselga J

Semiglazov V

van Dam P

Abstract

Purpose Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activity in preclinical models. This study explored whe...

Discussions